Literature DB >> 10639288

Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase.

H D Showalter1, A J Bridges, H Zhou, A D Sercel, A McMichael, D W Fry.   

Abstract

Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC(50)s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10639288     DOI: 10.1021/jm9903949

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  A simple and facile synthesis of tricyclic-fused pyrimido[4,5-b]indol-2-amines.

Authors:  Wentao Gao; Dongfang Wang; Yang Li
Journal:  Mol Divers       Date:  2017-06-19       Impact factor: 2.943

2.  Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.

Authors:  Ravi Kumar Vyas Devambatla; Wei Li; Nilesh Zaware; Shruti Choudhary; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem Lett       Date:  2017-05-27       Impact factor: 2.823

3.  Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.

Authors:  Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Bryan C Disch; Jessica E Thorpe; Anja Bastian; Michael A Ihnat
Journal:  Bioorg Med Chem       Date:  2013-01-31       Impact factor: 3.641

4.  Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.

Authors:  Kartik W Temburnikar; Sarah C Zimmermann; Nathaniel T Kim; Christina R Ross; Christopher Gelbmann; Christine E Salomon; Gerald M Wilson; Jan Balzarini; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem       Date:  2014-03-03       Impact factor: 3.641

5.  Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.

Authors:  Aleem Gangjee; Ying Zhao; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs; Roy L Kisliuk
Journal:  Bioorg Med Chem       Date:  2012-06-06       Impact factor: 3.641

6.  Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Authors:  Yujun Zhao; Longchuan Bai; Liu Liu; Donna McEachern; Jeanne A Stuckey; Jennifer L Meagher; Chao-Yie Yang; Xu Ran; Bing Zhou; Yang Hu; Xiaoqin Li; Bo Wen; Ting Zhao; Siwei Li; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2017-05-02       Impact factor: 7.446

7.  The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Michael A Ihnat; Aaron Buchanan
Journal:  Bioorg Med Chem Lett       Date:  2010-03-24       Impact factor: 2.823

Review 8.  A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship.

Authors:  Tanuja T Yadav; Gulam Moin Shaikh; Maushmi S Kumar; Meena Chintamaneni; Mayur Yc
Journal:  Front Chem       Date:  2022-06-13       Impact factor: 5.545

9.  Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.

Authors:  Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Michael Ihnat; Satyendra Shenoy; Roy L Kisliuk
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

10.  Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability.

Authors:  Stanislav Andreev; Tatu Pantsar; Ahmed El-Gokha; Francesco Ansideri; Mark Kudolo; Débora Bublitz Anton; Giulia Sita; Jenny Romasco; Christian Geibel; Michael Lämmerhofer; Márcia Ines Goettert; Andrea Tarozzi; Stefan A Laufer; Pierre Koch
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.